jRCT2071220034招募中不适用
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib (Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinib. )
Novartis Pharma. K.K.0 个研究点目标入组 30 人开始时间: 2023年2月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30
- 主要终点
- Annualized relapse rate (ARR) of confirmed relapses [Core Part]
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 55age old under（—）
- 性别
- All
入选标准
- •18 to 55 years of age
- •Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- •At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- •EDSS score of 0 to 5.5 (inclusive)
- •Neurologically stable within 1 month
排除标准
- •Diagnosis of primary progressive multiple sclerosis (PPMS)
- •Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
- •History of clinically significant CNS disease other than MS
- •Ongoing substance abuse (drug or alcohol)
- •History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer)
- •Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
- •suicidal ideation or behavior
- •Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
- •Participants who have had a splenectomy
- •Active clinically significant systemic bacterial, viral, parasitic or fungal infections
- •Positive results for syphilis or tuberculosis testing
- •Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
- •Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
- •Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
- •History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis or hepatic failure or participants with moderate or severe hepatic impairment (Child-Pugh class C) or any chronic liver or biliary disease.
- •History of severe renal disease or creatinine level
- •Participants at risk of developing or having reactivation of hepatitis
- •Hematology parameters at screening:
- •Hemoglobin: < 10 g/dl (<100g/L)
- •Platelets: < 100000/mm3 (<100 x 109/L)
- •Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- •White blood cells: <3 000/mm3 (<3.0 x 109/L)
- •Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- •B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
- •History or current diagnosis of significant ECG abnormalities
- •Resting QTcF >=450 msec (male) or >=460 msec (female) at pre-treatment (prior to randomization)
- •Use of other investigational drugs
- •Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
- •History of gastrointestinal bleeding
- •Major surgery within 8 weeks prior to screening
- •History of hypersensitivity to any of the study drugs or excipients
- •Pregnant or nursing (lactating) female participants, prior to randomization
- •Women of childbearing potential not using highly effective contraception
- •Sexually active males not agreeing to use condom
- •Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
- •Use of strong CYP3A4 inhibitors or strong CYP3A4 inducers within two weeks prior to randomization
结局指标
主要结局
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
时间窗: From Baseline, up to 30 month
ARR is the average number of confirmed MS relapses in a year
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treatment with remibrutinibMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple SclerosisEUCTR2020-005929-89-PLovartis Pharma AG800
进行中（未招募）
1 期
Study of efficacy and safety of ofatumumab compared to teriflunomide in patients with relapsing forms of multiple sclerosisMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2015-005419-33-HUovartis Pharma Services AG1,313
进行中（未招募）
1 期
Efficacy and safety of a progestin and an aromatase inhibitor combined in a intravaginal ring in symptomatic endometriosis.EndometriosisEUCTR2013-005090-53-BEBayer HealthCare AG318
招募中
3 期
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple SclerosisCTRI/2022/09/045669ovartis Healthcare Pvt Ltd
未知
3 期
A randomized, double-blind, double-dummy, parallel group, active controlled multi-center clinical trial to evaluate the additional efficacy and safety of Olmesartan Medoxomil/Amlodipine 20/5 mg in Chinese patients with mild or moderate essential hypertension who failed to achieve their goal with Olmesartan Medoxomil 20mg monotherapyEssential HypertensionJPRN-jRCT2080221543Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd.252